

Long-Term Efficacy and Safety of Oral Deucricitbant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Marcus Maurer^{1,2*}, Emel Aygören-Pürsün³, Laurence Bouillet⁴, Hugo Chapelaine⁵, Henriette Farkas⁶, Delphine Gobert⁷, Roman Hakl⁸, Ramon Lleonart⁹, Avner Reshef¹⁰, Giuseppe Spadaro¹¹, Maria Staevska¹², Marcin Stobiecki¹³, Justin Sun¹⁴, Li Zhu¹³, Ming Yu¹⁴, Giorgio Giannattasio¹⁵, Peng Lu¹⁴, Anna Valerieva¹²


¹Charité - Universitätsmedizin Berlin, Institute of Allergology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; ³University Hospital Frankfurt, Goethe University Frankfurt, Department for Children and Adolescents, Frankfurt, Germany; ⁴Grenoble Alpes University, Laboratoire T-RAIG, UMR 5525 TIMC-IMAG (UGA-CNRS), National Reference Center for Angioedema (CREAK), Department of Internal Medicine, Grenoble, France; ⁵CHU de Montréal, Université de Montréal, Montréal, QC, Canada; ⁶Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary; ⁷Sorbonne Université, Médecine Interne, AP-HP, Centre de référence des angioédèmes à kinines, Hôpital Saint-Antoine, Paris, France; ⁸St. Anne's University Hospital in Brno and Faculty of Medicine, Masaryk University, Department of Clinical Immunology and Allergology, Brno, Czech Republic; ⁹Bellvitge University Hospital, L'Hospitalet de Llobregat, Allergology Service, Barcelona, Spain; ¹⁰Barzilai University Hospital, Allergy, Immunology and Angioedema Center, Ashkelon, Israel; ¹¹University of Naples Federico II, Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), Napoli, Italy; ¹²Medical University of Sofia, Department of Allergology, Sofia, Bulgaria; ¹³Jagiellonian University Medical College, Department of Clinical and Environmental Allergology, Krakow, Poland; ¹⁴Pharvaris Inc., Lexington, MA, USA; ¹⁵Pharvaris GmbH, Zug, Switzerland; ¹⁶Pharvaris Inc., Lexington, MA, United States of America; ¹⁷Pharvaris GmbH, Zug, Switzerland.

Rationale


- International guidelines recommend that hereditary angioedema (HAE) attacks are treated as early as possible.^{1,3}
- The burden associated with parenteral administration of currently approved on-demand medications^{4,8} often leads to treatment of HAE attacks being delayed or forgone.⁹⁻¹³
- An unmet need exists for on-demand oral therapies that are effective and well tolerated and may reduce the treatment burden, thus enabling prompt administration.¹³
- Deucricitbant is a selective, orally-administered bradykinin B2 receptor antagonist under development for prophylactic and on-demand treatment of HAE attacks.¹⁴⁻¹⁹
- In the RAPIDe-1 Phase 2 trial (NCT04618211)¹⁴ deucricitbant immediate-release (IR) capsule reduced the time to onset of symptom relief and to resolution of HAE attacks vs placebo and was well tolerated.¹⁵

Methods

- RAPIDe-2 (NCT05396105)^{16†} is an ongoing, two-part Phase 2/3 extension study evaluating long-term safety and efficacy of orally-administered deucricitbant IR capsule for the treatment of HAE attacks.
- Part A enrolls adult (≥18 years) participants who completed RAPIDe-1. Participants continue self-administering the same double-blinded dose of deucricitbant IR capsule (10 mg, 20 mg, or 30 mg) received in RAPIDe-1 to treat qualifying non-laryngeal attacks (≥1 symptom with Visual Analogue Scale score ≥30), and laryngeal attacks presenting without breathing difficulties (Figure 1).



- The primary endpoint assesses safety, including treatment-emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiogram (ECG) findings.
- Patient-reported outcome (PRO) tools are used to assess efficacy (Figure 2), with data collection pre-specified at pre-treatment, every hour up to 6 hours, and then at 8, 12, 24, and 48 hours, from administration of deucricitbant IR capsule.
- Key efficacy endpoints (Figure 2) include:
 - Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints by 12 hours post-treatment.
 - Time to reduction in attack severity, defined as achieving ≥1-level reduction in the Patient Global Impression of Severity (PGI-S) from pre-treatment for 2 consecutive timepoints by 12 hours post-treatment.
 - Proportion of attacks achieving complete attack resolution, defined as achieving PGI-S rating of "none" at 24 hours post-treatment.



Results

- Data from the RAPIDe-2 Part A combined-dose group at the date of cutoff are reported here.
- A total of 265 attacks from 17 participants were included in the modified intention-to-treat efficacy analysis set at data cutoff (1 March 2024), defined as all participants who had ≥1 attack treated with deucricitbant and non-missing PGI-C results from ≥1 post-treatment timepoint.
- A total of 337 attacks from 19 participants were included in the safety analysis set at data cutoff (10 June 2024), defined as all participants who received any dose of deucricitbant in the study.
 - 7 of 337 attacks were laryngeal.
- Baseline characteristics were consistent with the RAPIDe-1 Phase 2 trial (Table 1).

Table 1. Baseline characteristics

	Deucricitbant IR capsule (combined dose group)
Number of attacks treated ^a	337
Number of participants ^a	19
Age in years, mean (SD)	42.7 (17.6)
Sex: Male/female, n (%)	7 (36.8) / 12 (63.2)
Race: White/other	18 / 1
BMI, mean (SD)	27.0 (3.8)
Years since HAE diagnosis, mean (SD)	21.7 (15.2)
HAE type, n (%)	
HAE-1	17 (89.5)
HAE-2	2 (10.5)

BMI, body mass index; HAE, hereditary angioedema; IR, immediate-release; SD, standard deviation. ^aNumber by the cutoff date (10 June 2024).

Safety

- Deucricitbant was well tolerated across all doses, with no treatment-related TEAEs (Table 2).
- No treatment-related serious or severe TEAEs, no treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings, and no TEAEs leading to treatment discontinuation, study withdrawal, or death were reported.

Table 2. TEAEs within 5 days after administration of study drug

Adverse events	Deucricitbant IR capsule (combined dose group)
Number of attacks treated ^a	337
Number of participants ^a	19
Attacks with any TEAE, n (%)	13 (3.9)
Treatment-related TEAEs, n	0
Serious TEAEs, n	1 ^b
Treatment-related serious TEAEs, n	0
TEAEs leading to study drug discontinuation, study withdrawal, or death, n	0


IR, immediate-release; TEAE, treatment-emergent adverse event (defined as adverse event occurring during time window from first study drug administration). ^aNumber in the safety analysis set at data cutoff (10 June 2024). ^bTooth caries unrelated to treatment.

Results

Efficacy

- The median time to onset of symptom relief was 1.1 hours (95% CI, 1.0, 1.2) (Figure 3, Table 3).
- 98.5% (261/265) of attacks achieved onset of symptom relief by 12 hours (Table 3, Figure 4).

Figure 3. Kaplan-Meier plot of time to onset of symptom relief



IR, immediate-release. ^aIncludes 10 mg, 20 mg, and 30 mg dose groups.


Table 3. Median time to achieving key efficacy endpoints

	Deucricitbant IR capsule (combined dose group)
Number of attacks treated ^a	265
Number of participants with treated attacks ^a	17
Median time to onset of symptom relief using PGI-C, hours (95% CI)	1.1 (1.0, 1.2)
Median time to reduction in attack severity using PGI-S, ^b hours (95% CI)	2.6 (2.0, 2.9)
Median time to complete attack resolution using PGI-S, ^b hours (95% CI)	11.5 (11.0, 13.0)

IR, immediate-release; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. ^aNumber in the modified intention-to-treat efficacy analysis set at data cutoff (01 March 2024). ^b261 attacks have non-missing pre-treatment PGI-S.

- 85.8% (224/261) of attacks achieved complete attack resolution by 24 hours (Figure 4).
- 90.2% (202/224) of attacks achieved this milestone with a single dose of deucricitbant IR capsule (Figure 6).


Figure 4. Proportion of attacks achieving key efficacy endpoints



PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. ^a261 attacks have non-missing pre-treatment PGI-S.


Results

Figure 5. Attacks treated with 1 or 2 doses of deucricitbant prior to achieving complete attack resolution



- A total of 86.0% (228/265) of all attacks were treated with a single dose of deucricitbant IR capsule (Figure 6).

Figure 6. Attacks treated with 1 or 2 doses of deucricitbant



Conclusions

- In the current analysis of the ongoing RAPIDe-2 Phase 2/3 extension study, deucricitbant IR capsule was well tolerated for all studied doses with no safety signals observed.
- Efficacy analysis showed:
 - 1.1 hours median time to onset of symptom relief using PGI-C – 98.5% of attacks by 12 hours.
 - 2.6 hours median time to reduction in attack severity using PGI-S – 97.7% of attacks by 12 hours.
 - 11.5 hours median time to complete attack resolution using PGI-S – 85.8% of attacks by 24 hours.
 - 86.0% of attacks were treated with a single dose of deucricitbant IR capsule.
- Results from the ongoing RAPIDe-2 extension are consistent with the Phase 2 RAPIDe-1 study and provide evidence on the long-term safety and efficacy of deucricitbant IR capsule for repeat treatment of HAE attacks.

References

- Betschel S, et al. *Allergy Asthma Clin Immunol*. 2019;15:72. 2. Busse PJ, et al. *J Allergy Clin Immunol Pract*. 2021;9:132-150. 3. Maurer M, et al. *Allergy*. 2022;77:1961-1990. 4. Beninet® [package insert], <https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf>. Accessed September 27, 2024. 5. Cinryze® [summary of product characteristics], https://www.ema.europa.eu/en/documents/product-information/cinryze-eepar-product-information_en.pdf. Accessed September 27, 2024. 6. Firazy® [package insert], https://www.shireconest.com/PI/PDF/Firazy_USA_ENG.pdf. Accessed September 27, 2024. 7. Kalbar® [package insert], https://www.shireconest.com/PI/PDF/Kalbar_USA_ENG.pdf. Accessed September 27, 2024. 8. Ruconest® [package insert], https://www.ruconest.com/wp-content/uploads/Ruconest_PLI_Apr2020.pdf. Accessed September 27, 2024. 9. Burnett A, et al. *AAAAI* 2023, Feb 24-27, San Antonio, TX, USA. 10. Tuong LA, et al. *Allergy Asthma Proc*. 2014;35:250-254. 11. US Food and Drug Administration. Center for Biologics Evaluation and Research. The voice of the patient—Hereditary angioedema. May 2016. <https://www.fda.gov/media/113509/download>. Accessed September 27, 2024. 12. Radjicic C, et al. Presented at AAAAI, Feb 24-27, 2023; San Antonio, TX, USA. 13. Mendivil J, et al. Presented at ACAAI, Nov 9-13, 2023; Anaheim, CA, USA. 14. <https://www.clinicaltrials.gov/study/NCT04618211>. Accessed September 27, 2024. 15. Maurer M, et al. Presented at AAAAI, Feb 24-27, 2023; San Antonio, TX, USA. 16. <https://clinicaltrials.gov/study/NCT05396105>. Accessed September 27, 2024. 17. <https://www.clinicaltrials.gov/study/NCT06343779>. Accessed September 27, 2024. 18. E. Aygören-Pürsün, et al. Presented at EAACI, May 31-June 3, 2024; Valencia, Spain. 19. <https://clinicaltrials.gov/study/NCT05047185>. Accessed September 27, 2024. 20. Cohn DM, et al. *Clin Transl Allergy*. 2023;e12288.

This presentation includes data for an investigational product not yet approved by regulatory authorities.